PYA
PYA
PYA is a national certified public accounting and professional services firm helping clients in 50 states derive value amid complex challenges related to federal and state filings, regulatory matters, compliance and risk assessment, business valuations, fair market value assessments, multi-unit business and clinical integrations, best practices, tax and assurance, governance, attestations, litigation support, mergers and acquisitions, operations optimization, and overall business strategy.
PYA’s comprehensive suite of services encompasses all strategic, operational, and health care transactional perspectives. The firm is committed to working alongside organizational leadership and front-line staff team members to mitigate risk and maximize overall compliance practices for organizations. PYA offers independent and objective valuation services–-key factors to sound business decisions.
Operational Support Solutions
Phone: 865.673.0844
Primary Contact
Merle Glasgow, Principal
MGlasgow@pyapc.com
215 Centerview Drive, Suite 330 Brentwood, TN 37027
Website: https://www.pyapc.com/
865.673.0844June 22, 2022
HHS awards $1M for health care innovation, boosting primary care access
The Department of Health & Human Services (HHS), in partnership with the Healthcare Resources & Services Administration (HRSA), announced the launch of a national competition offering a total of $1 million to spark healthcare innovation focused on boosting primary care access at HRSA-supported health centers.June 22, 2022
Keys to keeping Nebraska's rural hospital's doors open
Without federal intervention, a new report warns, rural hospitals across the United States, including many in Nebraska, could be forced to reduce services or even close their doors after pandemic relief funds expire.June 13, 2022
SUNRx 340B Webinar Series: 340B Regulatory Brief
The regulatory environment for 340B pharmacy is in a constant state of change, requiring eligible entities to be nimble and disciplined in the management of their program. Navigating the current ecosystem of 340B pricing limitations created by Big Pharma requires an understanding of the current regulatory environment.